trending Market Intelligence /marketintelligence/en/news-insights/trending/C8WCXqlbKrWrS_fwtNo7uw2 content esgSubNav
In This List

US FDA approves Lupin's generic dermatosis ointment

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


US FDA approves Lupin's generic dermatosis ointment

Lupin Ltd. received final approval from the U.S. FDA to market its desoximetasone ointment USP, 0.05%, a generic equivalent of Taro Pharmaceutical Industries Ltd.'s Topicort Ointment.

The ointment is for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.